Cardiol Therapeutics (CRDL) Competitors $1.09 -0.03 (-2.68%) Closing price 04:00 PM EasternExtended Trading$1.07 -0.02 (-1.83%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDL vs. EOLS, PRTC, REPL, CYRX, KMDA, AURA, IVA, CMPS, ESPR, and CMPXShould you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Evolus (EOLS), PureTech Health (PRTC), Replimune Group (REPL), CryoPort (CYRX), Kamada (KMDA), Aura Biosciences (AURA), Inventiva (IVA), COMPASS Pathways (CMPS), Esperion Therapeutics (ESPR), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry. Cardiol Therapeutics vs. Its Competitors Evolus PureTech Health Replimune Group CryoPort Kamada Aura Biosciences Inventiva COMPASS Pathways Esperion Therapeutics Compass Therapeutics Evolus (NASDAQ:EOLS) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation. Is EOLS or CRDL more profitable? Cardiol Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -22.31%. Cardiol Therapeutics' return on equity of -232.26% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-22.31% -759.04% -24.63% Cardiol Therapeutics N/A -232.26%-158.19% Do insiders & institutionals believe in EOLS or CRDL? 90.7% of Evolus shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 5.9% of Evolus shares are held by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, EOLS or CRDL? Evolus has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Does the media favor EOLS or CRDL? In the previous week, Evolus had 7 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 8 mentions for Evolus and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 1.14 beat Evolus' score of 1.04 indicating that Cardiol Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Evolus Positive Cardiol Therapeutics Positive Which has preferable earnings and valuation, EOLS or CRDL? Cardiol Therapeutics has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$277.94M1.75-$50.42M-$0.98-7.67Cardiol TherapeuticsN/AN/A-$26.77M-$0.34-3.21 Do analysts rate EOLS or CRDL? Evolus presently has a consensus price target of $21.25, indicating a potential upside of 182.58%. Cardiol Therapeutics has a consensus price target of $8.00, indicating a potential upside of 633.94%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Evolus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryCardiol Therapeutics beats Evolus on 9 of the 16 factors compared between the two stocks. Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDL vs. The Competition Export to ExcelMetricCardiol TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$91.24M$2.79B$5.76B$9.84BDividend YieldN/A1.68%3.95%4.02%P/E Ratio-3.2122.8231.3126.60Price / SalesN/A742.71461.30121.37Price / CashN/A177.7737.7659.36Price / Book10.906.1810.026.67Net Income-$26.77M$32.94M$3.27B$265.59M7 Day Performance-6.84%0.99%3.17%3.42%1 Month Performance-28.76%1.69%4.34%1.09%1 Year Performance-43.23%11.45%44.11%23.85% Cardiol Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDLCardiol Therapeutics2.356 of 5 stars$1.09-2.7%$8.00+633.9%-42.0%$91.24MN/A-3.2120Positive NewsGap UpHigh Trading VolumeEOLSEvolus4.126 of 5 stars$6.69-0.6%$21.25+217.6%-52.2%$435.33M$266.27M-6.83170Positive NewsGap UpPRTCPureTech Health2.9144 of 5 stars$19.84+10.2%$45.00+126.8%-28.0%$434.61M$4.83M0.00100News CoveragePositive NewsGap DownREPLReplimune Group3.9093 of 5 stars$5.33-4.1%$7.67+43.8%-44.6%$433.99MN/A-1.65210CYRXCryoPort3.8565 of 5 stars$8.79+2.1%$12.00+36.5%-0.7%$431.08M$237.88M6.611,186Positive NewsKMDAKamada4.7534 of 5 stars$7.17-2.4%$13.00+81.3%+26.0%$422.66M$160.95M21.09360Positive NewsAURAAura Biosciences1.7278 of 5 stars$6.69-0.4%$22.00+228.8%-15.6%$417.45MN/A-3.4150Positive NewsIVAInventiva3.1857 of 5 stars$4.59+5.3%$10.40+126.6%+115.2%$417.09M$9.95M0.00100News CoverageAnalyst ForecastGap UpCMPSCOMPASS Pathways2.4069 of 5 stars$4.26-1.4%$16.29+282.3%-41.0%$414.47MN/A-2.32120News CoveragePositive NewsESPREsperion Therapeutics3.7816 of 5 stars$2.10+2.4%$7.00+233.3%+27.5%$413.33M$268.13M-4.29200News CoverageAnalyst DowngradeCMPXCompass Therapeutics2.2155 of 5 stars$2.87-3.4%$12.89+349.1%+160.3%$410.70M$850K-6.3820 Related Companies and Tools Related Companies EOLS Alternatives PRTC Alternatives REPL Alternatives CYRX Alternatives KMDA Alternatives AURA Alternatives IVA Alternatives CMPS Alternatives ESPR Alternatives CMPX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRDL) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access